Alkermes plc. ALKS
Alkermes plc. (Nasdaq: ALKS) is a CNS/neurology/psychiatry drug developer. Its lead program, Alixorexton, is in Phase 3 for Narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ARISTADA | Schizophrenia | small molecule | Approved |
| ARISTADA INITIO | Initiation of ARISTADA for schizophrenia | small molecule | Approved |
| LUMRYZ | Narcolepsy (cataplexy or EDS) in adults and pediatric patients ≥7 years | small molecule | Approved |
| LYBALVI | Schizophrenia; Bipolar I disorder | small molecule | Approved |
| VIVITROL | Alcohol dependence; Opioid dependence | small molecule | Approved |
| Alixorexton | Narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2) | small molecule | Phase 3 |
| LUMRYZ | Idiopathic hypersomnia (IH) | small molecule | Phase 3 |
| Alixorexton | Idiopathic hypersomnia (IH) | small molecule | Phase 2 |
| ALKS 7290 | ADHD | small molecule | Phase 2 |
| ALKS 7290 | Major depressive disorder (MDD) - adjunctive therapy | small molecule | Phase 2 |
Recent results and decisions
- Nov 3, 2026started Alkermes initiated a phase 2 study of an orexin 2 receptor agonist in major depressive disorder.
The rapid expansion of our orexin development programs, highlighted by our recent clinical proof-of-concept data in ADHD and initiation of a phase 2 study in major depressive disorder
Filing - Nov 3, 2026positive Alkermes reported recent clinical proof-of-concept data for an orexin 2 receptor agonist in ADHD.
The rapid expansion of our orexin development programs, highlighted by our recent clinical proof-of-concept data in ADHD
Filing - Nov 3, 2026met Alkermes reported positive topline results from a phase 3 study of LUMRYZ in idiopathic hypersomnia.
In connection with the positive topline results of the LUMRYZ phase 3 study in idiopathic hypersomnia, the Company recorded an increase of $26.4 million in the fair value of contingent consideration
Filing
4 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.